Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, March 10, 2023
[ Fri, Mar 10th 2023
] - WOPRAI
[ Fri, Mar 10th 2023
] - WOPRAI
[ Fri, Mar 10th 2023
] - WOPRAI
[ Fri, Mar 10th 2023
] - WOPRAI
[ Fri, Mar 10th 2023
] - WOPRAI
[ Fri, Mar 10th 2023
] - WOPRAI
[ Fri, Mar 10th 2023
] - WOPRAI
[ Fri, Mar 10th 2023
] - WOPRAI
[ Fri, Mar 10th 2023
] - WOPRAI
[ Fri, Mar 10th 2023
] - WOPRAI
[ Fri, Mar 10th 2023
] - WOPRAI
[ Fri, Mar 10th 2023
] - WOPRAI
[ Fri, Mar 10th 2023
] - WOPRAI
[ Fri, Mar 10th 2023
] - WOPRAI
[ Fri, Mar 10th 2023
] - WOPRAI
[ Fri, Mar 10th 2023
] - WOPRAI
[ Fri, Mar 10th 2023
] - WOPRAI
[ Fri, Mar 10th 2023
] - WOPRAI
[ Fri, Mar 10th 2023
] - WOPRAI
[ Fri, Mar 10th 2023
] - WOPRAI
[ Fri, Mar 10th 2023
] - WOPRAI
[ Fri, Mar 10th 2023
] - WOPRAI
[ Fri, Mar 10th 2023
] - WOPRAI
[ Fri, Mar 10th 2023
] - WOPRAI
[ Fri, Mar 10th 2023
] - WOPRAI
[ Fri, Mar 10th 2023
] - WOPRAI
[ Fri, Mar 10th 2023
] - WOPRAI
[ Fri, Mar 10th 2023
] - WOPRAI
[ Fri, Mar 10th 2023
] - WOPRAI
[ Fri, Mar 10th 2023
] - WOPRAI
Balaji Prasad Maintained (AMRX) at Buy with Decreased Target to $4 on, Mar 10th, 2023
Balaji Prasad of Barclays, Maintained "Amneal Pharmaceuticals, Inc." (AMRX) at Buy with Decreased Target from $7 to $4 on, Mar 10th, 2023.
Balaji has made no other calls on AMRX in the last 4 months.
There are 2 other peers that have a rating on AMRX. Out of the 2 peers that are also analyzing AMRX, 1 agrees with Balaji's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Gary Nachman of "BMO Capital" Maintained at Hold with Decreased Target to $4 on, Friday, March 3rd, 2023
This is the rating of the analyst that currently disagrees with Balaji
- Nathan Rich of "Goldman Sachs" Maintained at Strong Buy with Decreased Target to $3 on, Friday, March 3rd, 2023
